Cost-effectiveness analysis of isolation strategies for asymptomatic and mild symptom COVID-19 patients
Issued Date
2023-12-01
Resource Type
eISSN
14787547
Scopus ID
2-s2.0-85176137464
Journal Title
Cost Effectiveness and Resource Allocation
Volume
21
Issue
1
Rights Holder(s)
SCOPUS
Bibliographic Citation
Cost Effectiveness and Resource Allocation Vol.21 No.1 (2023)
Suggested Citation
Suthutvoravut U., Kunakorntham P., Semayai A., Tansawet A., Pattanaprateep O., Piebpien P., Numthavaj P., Thakkinstian A., Atiksawedparit P. Cost-effectiveness analysis of isolation strategies for asymptomatic and mild symptom COVID-19 patients. Cost Effectiveness and Resource Allocation Vol.21 No.1 (2023). doi:10.1186/s12962-023-00497-x Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/91068
Title
Cost-effectiveness analysis of isolation strategies for asymptomatic and mild symptom COVID-19 patients
Author's Affiliation
Other Contributor(s)
Abstract
Background: Management of COVID-19 patients with mild and moderate symptoms could be isolated at home isolation (HI), community isolation (CI) or hospitel. However, it was still unclear which strategy was more cost-effective. Therefore, this study was conducted to evaluate this. Methods: This study used data from patients who initially stayed at HI, CI, and hospitel under supervision of Ramathibodi Hospital between April and October 2021. Outcomes of interest were hospitalisation and mortality. An incremental cost-effectiveness ratios (ICER) was calculated based on hospital perspective using home isolation as the reference. Results: From 7,077 patients, 4,349 2,356, and 372 were admitted at hospitel, HI, and CI, respectively. Most patients were females (57.04%) and the mean age was 40.42 (SD = 16.15). Average durations of stay were 4.47, 3.35, and 3.91 days for HI, CI, and hospitel, respectively. The average cost per day for staying in these corresponding places were 24.22, 63.69, and 65.23 US$. For hospitalisation, the ICER for hospitel was at 41.93 US$ to avoid one hospitalisation in 1,000 patients when compared to HI, while CI had more cost, but less cases avoided. The ICER for hospitel and CI were at 46.21 and 866.17 US$ to avoid one death in 1,000 patients. Conclusions: HI may be cost-effective isolated strategy for preventing hospitalisation and death in developing countries with limited resources.